MedTrace Logo

Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)

NCT01448655 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2013-07-02

No results posted yet for this study

Summary

Efficacy and safety of a supportive treatment with European mistletoe extract Iscador® Qu ("quercus", i.e. from oak tree) in patients with colorectal cancer (Union for International Cancer Control, UICC stages II-IV), in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy) as compared to a parallel group with conventional therapy only.

Primary Endpoints: Reduction of adverse effects of conventional therapy; reduction of therapy or disease induced symptoms (both are quality of life parameters and evaluated after 1 year); prolongation of disease free and/or overall survival (DFS, OS) after 5 years.

Prospective observational confirmation study of previous retrospective cohort study.

As this is a non-interventional cohort study, all therapies and measurements are performed on directive by the treating physician and/or request by the patient only.

Conditions

Sponsors & Collaborators

  • Hiscia Society for Cancer Research

    collaborator UNKNOWN

  • IFAG Basel AG (CRO), both Switzerland

    collaborator UNKNOWN

  • IFAG AG

    lead INDUSTRY

Principal Investigators

  • Thomas Seufferlein, Prof. M.D. · University Clinic Halle (Saale)

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2016-12-31
Completion
2017-06-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448655 on ClinicalTrials.gov